Search Results
Your search for ,WHo matches 20189 pages
Showing 3851 - 3900
Benoit You, MD, PhD, on Ovarian Cancer: Who Benefits From Bevacizumab in the First-Line Setting
Benoit You, MD, PhD, of Lyon University hospital (HCL, France) and GINECO group (France), discusses findings from the GOG-0218 trial of patients with ovarian cancer, which appears to confirm earlier data on the link between poor tumor chemosensitivity and benefit from concurrent plus maintenance...
Brentuximab Vedotin Plus Chemotherapy vs Chemotherapy Alone for Pediatric Patients With Hodgkin Lymphoma
A new study has shown that a combination of brentuximab vedotin and standard chemotherapy is safe and appears to be more effective than standard chemotherapy in pediatric patients up to age 21 with newly diagnosed high-risk Hodgkin lymphoma. Findings from the Children's Oncology Group phase III...
Including ASCT as Part of Initial Therapy Improves Progression-Free Survival in Newly Diagnosed Patients With Multiple Myeloma
The use of autologous stem cell transplantation (ASCT) early in the course of treatment showed a significant 21.4-month gain in median progression-free survival in younger, newly diagnosed patients with multiple myeloma compared with patients who received chemotherapy without an initial...
Fam-Trastuzumab Deruxtecan-nxki Doubles Progression-Free Survival in HER2-Low Metastatic Breast Cancer
The use of fam-trastuzumab deruxtecan-nxki doubled progression-free survival compared with the standard-of-care treatment plus conventional chemotherapy. It also significantly improved overall survival for patients with metastatic breast cancers expressing low levels of the HER2 receptor,...
Panitumumab Plus mFOLFOX6 Improves Overall Survival in a Type of Newly Diagnosed Metastatic Colorectal Cancer
The use of panitumumab plus mFOLFOX6 significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer that was classified as left-sided compared with patients who received mFOLFOX6 plus bevacizumab, according to findings presented during the Plenary Session by...
Endocrine Sensitivity Test Predicts Survival Benefit of Dose-Dense Chemotherapy for Patients With Hormone Receptor–Positive Breast Cancer
A new genomic test designed to measure the endocrine sensitivity of estrogen receptor–positive breast cancer has the potential to identify patients diagnosed with the disease who could benefit more from dose-dense chemotherapy—a regimen in which chemotherapy is administered more frequently than...
Study Reveals Racial Disparities in Guideline-Concordant Care for Patients With Early-Onset Colorectal Cancer
In a large national study, Black patients diagnosed with early-onset colorectal cancer received worse and less timely care than their White counterparts. Differences in health insurance coverage type, a modifiable factor, according to the findings, accounted for the largest identified contributor...
Adagrasib Improves Outcomes in KRAS-Mutated NSCLC, Phase II Study Shows
Nearly 43% of patients with non–small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of...
ASCO and WHO to Collaborate on Quality Indicators for Cancer Facilities
In a collaboration announced today, ASCO will work with the World Health Organization (WHO) to measure and improve the quality of cancer care internationally. The goal is to achieve health-related targets of the United Nations Sustainable Development Goals and WHO Global Action Plan on...
ctDNA May Help Identify the Need for Adjuvant Therapy in Stage II Colon Cancer
In patients with stage II colon cancer where cancer DNA was not present in the blood (as circulating tumor DNA, or ctDNA), adjuvant chemotherapy could be skipped without compromising recurrence-free survival. Conversely, for patients where ctDNA was present after surgery, the rate of recurrence...
Sacituzumab Govitecan-hziy Improves Progression-Free Survival in Endocrine-Resistant Hormone Receptor–Positive/HER2-Negative Metastatic Breast Cancer
Treatment with the antibody-drug conjugate sacituzumab govitecan-hziy resulted in longer progression-free survival compared to physician’s choice of chemotherapy in patients who have received many prior therapies for hormone receptor–positive/HER2-negative metastatic breast cancer, according to...
Nemvaleukin Alfa Alone and in Combination With Pembrolizumab for Advanced-Stage Solid Tumors
Initial results from the ARTISTRY-1 study to be presented by Vaishampayan et al at the 2022 ASCO Annual Meeting showed that an experimental drug called nemvaleukin alfa, when used alone or in combination with pembrolizumab, may be effective in treating several types of late-stage cancers in some...
Survival and Surgery-to-Radiotherapy Intervals Among Asian American and Pacific Islander Women With Early Breast Cancer
In a study reported in JCO Oncology Practice, Taparra et al identified differences in 10-year survival and surgery-to-radiotherapy intervals among disaggregated Asian American and Native Hawaiian/other Pacific Islander women with early-stage breast cancer. The study used National Cancer Database...
New Study Assesses Oncologists’ Ratings of the Importance of Health Insurance and Costs for Genomic Testing
A new study led by researchers at the American Cancer Society showed physician, practice, and patient characteristics were associated with oncologists’ ratings of the importance of patient health insurance and out-of-pocket costs for genomic testing in treatment decisions. The findings are being...
Nimotuzumab May Improve Overall Survival in Patients With KRAS Wild-Type Advanced Pancreatic Cancer
The addition of nimotuzumab, an EGFR-targeting monoclonal antibody, to gemcitabine increased overall survival in patients with KRAS wild-type advanced pancreatic cancer, particularly those who did not need surgery for obstruction of a pancreatic bile duct, according to data from the phase III...
Jeremy Abramson, MD, Comments on Results From the SHINE Trial
Jeremy Abramson, MD, Director of the Jon and Jo Ann Hagler Center for Lymphoma at Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School, was enthusiastic about these data. “These important data show that ibrutinib added to bendamustine/rituximab ...
Ibrutinib Added to Standard Therapy Prolongs Progression-Free Survival in Older Patients With Mantle Cell Lymphoma
Primary results from the phase III SHINE trial demonstrated that first-line treatment with ibrutinib combined with bendamustine/rituximab and rituximab maintenance achieves a substantial prolongation of progression-free survival in elderly patients with mantle cell lymphoma, according to a...
New Interactive Map of Oncology Puts COVID-19, Equity Data Into Perspective
In an effort to highlight cancer care inequities during the COVID-19 pandemic, ASCO has launched the Interactive Map of Oncology, a data visualization tool that allows users to explore geographic distribution of systemic and socioeconomic factors that influence cancer care delivery in the United...
Postoperative Outcomes With Robot-Assisted vs Open Radical Cystectomy for Bladder Cancer
As reported in JAMA by Catto et al, the phase III iROC trial showed that robot-assisted radical cystectomy with intracorporeal urinary diversion resulted in better 90-day outcomes compared with open radical cystectomy in patients with bladder cancer. Study Details In the multicenter trial, 338...
Vaccine Effectiveness Against COVID-19 Breakthrough Infection in Patients With Cancer
In a population-based study based on data from the UK Coronavirus Cancer Evaluation Project (UKCCEP) reported in The Lancet Oncology, Lennard Y.W. Lee, DPhil, and colleagues found that COVID-19 vaccination was effective in preventing breakthrough infection among patients with cancer but less...
Addition of Adebrelimab to Carboplatin/Etoposide in First-Line Treatment of Extensive-Stage SCLC
In a Chinese phase III trial (CAPSTONE-1) reported in The Lancet Oncology, Jie Wang, MD, PhD, and colleagues found that the addition of adebrelimab, a novel anti–PD-L1 antibody, to carboplatin and etoposide significantly improved overall survival as a first-line treatment for patients with...
New FDA-Approved Oncology Drugs (2021–2022)
Over the past year (May 2021–May 2022), the U.S. Food and Drug Administration (FDA) approved and expanded indications for many drugs related to the treatment of different types of cancers and adverse events. The new approvals and accelerated approvals are listed below. FAM-TRASTUZUMAB...
A Global Humanist of Heroic Proportions Who Never Lost Sight of the Wounded Living in the Shadows of Poverty
Global health crusader Paul Farmer, MD, PhD, had a wildly unconventional childhood, which helped inform his adult life as a medical humanitarian. Dr. Farmer was born in West Adams, a town that lies along the verdant valley surrounding the Hoosic River in northern Massachusetts. He was the second of ...
ASCO Establishes Center for Equity, Diversity, and Inclusion: Sybil Green, JD, RPh, MHA, to Serve as Center’s Vice President
On April 12, 2022, ASCO announced the establishment of the ASCO Center for Equity, Diversity, and Inclusion, which will advance the Society’s equity, diversity, and inclusion (EDI) goals across the organization and throughout the wider oncology community. ASCO Chief Equity, Diversity, and Inclusion ...
City of Hope’s Department of Surgery Chair Awarded 2022 Flance-Karl Award, Given by the American Surgical Association
Yuman Fong, MD, Chair of City of Hope’s Department of Surgery and Director of its Center for Surgical Innovation, has been named a recipient of the 2022 Flance-Karl Award by the American Surgical Association (ASA). The award is given annually to one surgeon in the United States who has made...
Lynn M. Schuchter, MD, FASCO, to Become ASCO President-Elect, 2022–2023, Following Annual Meeting
Individuals elected to ASCO leadership for the 2022–2023 term were announced earlier in the year. ASCO elected Lynn M. Schuchter, MD, FASCO, a long-time member and volunteer, to serve as its President beginning in June 2023. Dr. Schuchter will take office as President-Elect immediately after the...
City of Hope Researcher Receives Margaret L. Kripke Legend Award for Promotion of Women in Cancer
Leslie Bernstein, PhD, Director of City of Hope’s Division of Biomarkers of Early Detection and Prevention, received the Margaret L. Kripke Legend Award for Promotion of Women in Cancer Medicine and Cancer Science. Dr. Bernstein has made a substantial mark on both science and society by...
Turning Point
On a cool, gray November morning, I took the call from a walk-in doctor about Carla, a 26-year-old woman with progressive lymphadenopathy who was refusing investigations because of severe needle phobia. Carla was willing to meet with me to discuss treatment options for a suspected diagnosis of...
An International Leader Bridges the Political Divide in the Name of Humanity and Cancer Care
Michael Silbermann, DMD, PhD, was born on January 19, 1935, in the old quarter of Acre, a northern Arab city stretching along the north end of the Bay of Haifa in present-day Israel. “Acre, which was developed more than 4,000 years ago, was one of the primary harbors of the Phoenician people....
NCI Launches Program to Offer Molecular Characterization of Childhood Cancers
In support of President Biden’s Cancer Moonshot goal of fostering data sharing in cancer research, the National Cancer Institute (NCI), which is part of the National Institutes of Health, has launched the Molecular Characterization Initiative for pediatric tumors. This program offers tumor...
Growing Up in a House Filled With Science Leads to a Career in Breast Cancer and Health Outcomes Research
Debra Patt, MD, PhD, MBA, Executive Vice President of Policy and Strategic Initiatives for Texas Oncology, was reared in Plano, Texas, a city in the sprawling Dallas–Fort Worth metroplex. “My father was an electrical engineer with a PhD, and all throughout my childhood, I was exposed to the wonders ...
A Community Practitioner and Policy Advocate Who Stresses Holistic, Patient-Centered Care
Community practices have long been a keystone of our nation’s oncology care delivery system by allowing patients with cancer to receive specialized treatment near their homes and places of business. Innovative clinicians in the community setting are also leading efforts to create a more efficient...
A Nationally Regarded Pediatric Oncologist Found His Passion Early
ASCO Past President, Michael Link, MD, who has pioneered new strategies for treating common childhood cancers, was born and reared in a suburb of Cleveland. “My first significant exposure to medicine was my own family doctor, Dr. J.W. Epstein. Looking back, I was impressed by the combination of...
Mount Sinai and Samuel Waxman Cancer Research Foundation to Collaborate on Aging-Related Cancer
The Tisch Cancer Institute (TCI) at Mount Sinai and the Samuel Waxman Cancer Research Foundation (SWCRF) are launching a unique research program that will fund collaborations between TCI physician-scientists and colleagues from other established cancer research institutions to address the worldwide ...
ASCO Expands Oncology Summer Internship Program With Aims to Increase Workforce Diversity
ASCO recently announced six additional medical schools will participate in the second year of the Oncology Summer Internship (OSI) program, an immersive, 4-week summer internship for rising second-year medical students from groups underrepresented in medicine (UIM).1 In 2022, ASCO and a total of 11 ...
Sunil Verma, MD, Navigates an International Path From Clinical Educator in Oncology to Leadership in Industry
In this installment of The ASCO Post’s Living a Full Life series, guest editor, Jame Abraham, MD, spoke with Sunil Verma, MD, the Global Head of Oncology, Medical, at AstraZeneca. Sunil Verma, MD, was born in Zambia, a landlocked country at the crossroads of Central, Southern, and East Africa. “My...
Navigating Difficult Waters: A Cancer Journey
In the summer of 2017, while visiting Normandy, 64-year-old Mark’s right testis became enlarged and tender. His initial workup identified a large testicular Leydig cell tumor with adverse pathologic features; computed tomography showed no evidence of metastasis.1,2 His medical history was otherwise ...
A Fascination With Bats Leads to a Career in Oncology and a Role in Championing Equity in the Workforce
According to internationally regarded neuroendocrine tumor specialist, Pamela Kunz, MD, her career path was kickstarted by childhood bat-hunting expeditions in barns and caves throughout rural New England. “My father was an environmental biologist at Boston University who studied bats. Although at...
A Descendant of Midwest Pioneers Follows a Path to Academic Genitourinary Oncology
Prior to the birth of the steel industry, Luxembourg was a poor and rural country. At the start of the 19th century, many Luxembourgers searching opportunity emigrated to the United States. The hardiest among them ventured into the Great Plains region to take advantage of homesteading...
Missed Opportunities in Geriatric Oncology Research
The underrepresentation of older patients (≥ 65 years) in clinical trials has been well documented for more than 20 years. This has been an issue at all phases of drug development, including pivotal trials for drug approvals,1 despite the fact that many of these new therapeutics will primarily be...
From the Segregated Tennis Courts of Washington, DC, to a Leadership Role in Surgical Oncology
Success in tennis demands precision timing, extraordinary hand-eye dexterity, and commanding mental and physical vigor. According to Harold P. Freeman, MD, the discipline and skills he learned on the tennis courts at an early age stood him in good stead during his remarkable life’s journey. “My...
A Leader in Oncology Balances Philosophy, Medicine, and Humility
"The reality is that closure is a myth. My personal and professional experience with those who have lost friends and family, including children, has taught me that going on with life is not the same as gaining closure. The wound of loss is a part of each person’s life forever,” wrote...
A Son Forges a Noted Career in Oncology Rather Than Follow in His Father’s Illustrious Footsteps in Dermatology
Rakesh Chopra, MD, former Chairman and Head of the Oncology Department of Artemis Hospitals, was born in New Delhi, the capital of modern India. As a child, he attended the Lawrence School, Sanawar, a private boarding school in Himachal Pradesh, among beautiful sylvan surroundings. “Sanawar was...
ASCO Honors 2022 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2022 ASCO Annual Meeting in Chicago. “This year’s Special...
A Personal Cancer Journey Shifts a Career in the Arts to a Career in Radiation Oncology
It is safe to assume that most oncologists take a fairly straight career path, beginning with the decision to become a doctor. Along the educational journey from medical school to fellowship, an event or mentor usually incites the passion to pursue the challenging field of oncology. Although Fumiko ...
After Rounds on the Leukemia Ward, a Young Doctor Finds His Calling in Stem Cell Transplantation
Internationally recognized stem cell transplant pioneer Richard E. Champlin, MD, was born in Milwaukee and moved to Homewood, a suburb on the southern lip of Chicago, with his parents when he was 3 years old. Following high school, Dr. Champlin entered Purdue University in Indiana to pursue a...
FDA Approves Tisagenlecleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma
On May 28, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy....
Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Stage IIIA NSCLC: Overall Survival and Biomarker Analyses
In analyses from a Spanish phase II trial (NADIM) reported in the Journal of Clinical Oncology, Provencio et al found a high rate of 3-year overall survival in patients with operable stage IIIA non–small cell lung cancer (NSCLC) who received neoadjuvant nivolumab plus chemotherapy. Survival was...
Association of Chronic Hepatitis B Virus Infection and Antiviral Treatment With Risk of Extrahepatic Malignancies
In a Korean nationwide cohort study reported in the Journal of Clinical Oncology, Lee et al found that patients with chronic hepatitis B infection were at increased risk of extrahepatic malignancies, with risk being reduced among those receiving nucleoside/nucleotide analog antiviral treatment for...
No Good Treatment Options, So I’ll Eat Ice Cream
On a warm summer afternoon, I stood in front of tables at the local farmers market loaded with my favorite fruits and vegetables: peaches, tomatoes, corn, peppers, melons, kale. I practically drooled thinking about what I could make that week: corn and tomato salad, kale and mushroom quesadillas,...
